Krystal Biotech (KRYS) Shares Up 3.5% Following Analyst Upgrade

Krystal Biotech Inc (NASDAQ:KRYS) shot up 3.5% during trading on Tuesday after HC Wainwright raised their price target on the stock from $32.00 to $35.50. HC Wainwright currently has a buy rating on the stock. Krystal Biotech traded as high as $21.90 and last traded at $20.70. 3,230 shares traded hands during trading, a decline of 91% from the average session volume of 35,064 shares. The stock had previously closed at $20.00.

Other equities research analysts have also issued research reports about the stock. Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of Krystal Biotech in a research note on Monday, August 6th. Cantor Fitzgerald began coverage on shares of Krystal Biotech in a research note on Monday, September 10th. They set an “overweight” rating and a $28.00 price objective on the stock. William Blair began coverage on shares of Krystal Biotech in a research note on Tuesday, July 10th. They set an “outperform” rating on the stock. Zacks Investment Research raised shares of Krystal Biotech from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Saturday, August 11th. Finally, LADENBURG THALM/SH SH set a $38.00 price objective on shares of Krystal Biotech and gave the stock a “buy” rating in a research note on Thursday, July 19th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $32.30.

An institutional investor recently raised its position in Krystal Biotech stock. BlackRock Inc. lifted its position in Krystal Biotech Inc (NASDAQ:KRYS) by 75.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 13,040 shares of the company’s stock after buying an additional 5,607 shares during the period. BlackRock Inc. owned about 0.13% of Krystal Biotech worth $194,000 as of its most recent SEC filing. Institutional investors own 23.07% of the company’s stock.

The company has a market capitalization of $182.02 million and a PE ratio of -14.47.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.12. As a group, equities research analysts forecast that Krystal Biotech Inc will post -1.01 earnings per share for the current year.

Krystal Biotech Company Profile (NASDAQ:KRYS)

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.

Further Reading: What are the components of an earnings report?

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply